- Home
- KALA vs GOVX Comparison
KALA vs GOVX Comparison
Compare KALA & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- GOVX
- Stock Information
- Founded
- KALA 2009
- GOVX 2001
- Country
- KALA United States
- GOVX United States
- Employees
- KALA N/A
- GOVX N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- KALA Health Care
- GOVX Health Care
- Exchange
- KALA Nasdaq
- GOVX Nasdaq
- Market Cap
- KALA 27.3M
- GOVX 23.8M
- IPO Year
- KALA 2017
- GOVX N/A
- Fundamental
- Price
- KALA $7.69
- GOVX $2.11
- Analyst Decision
- KALA Strong Buy
- GOVX Strong Buy
- Analyst Count
- KALA 2
- GOVX 5
- Target Price
- KALA $15.00
- GOVX $14.20
- AVG Volume (30 Days)
- KALA 47.7K
- GOVX 691.5K
- Earning Date
- KALA 11-12-2024
- GOVX 02-27-2025
- Dividend Yield
- KALA N/A
- GOVX N/A
- EPS Growth
- KALA N/A
- GOVX N/A
- EPS
- KALA N/A
- GOVX N/A
- Revenue
- KALA N/A
- GOVX $3,090,161.00
- Revenue This Year
- KALA N/A
- GOVX N/A
- Revenue Next Year
- KALA N/A
- GOVX $150.51
- P/E Ratio
- KALA N/A
- GOVX N/A
- Revenue Growth
- KALA N/A
- GOVX N/A
- 52 Week Low
- KALA $4.21
- GOVX $1.09
- 52 Week High
- KALA $8.79
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- KALA 61.19
- GOVX 40.27
- Support Level
- KALA $7.00
- GOVX $2.04
- Resistance Level
- KALA $8.79
- GOVX $2.32
- Average True Range (ATR)
- KALA 0.61
- GOVX 0.18
- MACD
- KALA 0.05
- GOVX -0.02
- Stochastic Oscillator
- KALA 51.97
- GOVX 9.86
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.